Immunogenicity and Safety of Half-Dose Heterologous mRNA-1273 Booster Vaccination for Adults Primed with the CoronaVac® and ChAdOx1-S Vaccines for SARS-CoV-2
Authors:
- Nina Dwi PutriNPNina Dwi Putri
- Aqila Sakina ZhafiraAZAqila Sakina Zhafira
- Pratama WicaksanaPWPratama Wicaksana
- Robert SintoRSRobert Sinto
- Gryselda HanafiGHGryselda Hanafi
- Lowilius WiyonoLWLowilius Wiyono
- Ari PrayitnoAPAri Prayitno
- Mulya Rahma KaryantiMKMulya Rahma Karyanti
- Murni Luciana NaibahoMNMurni Luciana Naibaho
- Febrina FebrinaFFFebrina Febrina
- Hadyana SukandarHSHadyana Sukandar
- Vivi SetiawatyVSVivi Setiawaty
Open Access
Abstract
Coronavirus disease 2019 (COVID-19) has been extensively researched, particularly with regard to COVID-19 vaccines. However, issues with logistics and availability might cause delays in vaccination programs. Thus, the efficacy and safety of half-dose heterologous mRNA should be explored. This was an open-label observational study to evaluate the immunogenicity and safety of half-dose mRNA-1273 as a booster vaccine among adults aged >18 years who underwent a complete primary SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination regimen with CoronaVac® and ChAdOx1-S. Adverse events (AEs), seropositivity rate, seroconversion, geometric mean titer (GMT) of SARS-CoV-2 antibodies, neutralizing antibodies, and T cells (CD4+ and CD8+) specific for SARS-CoV-2 were analyzed. Two hundred subjects were included in the final analysis, with 100 subjects in each priming vaccine group. Most of the AEs were mild, with systemic manifestations occurring between 1 and 7 days following vaccination. A significant difference was observed in the GMT and seropositivity rate following booster dose administration between the two groups. CD8+/CD3+, IFN (interferon)-producing CD8+, and TNF (tumor necrosis factor)-producing CD8+ cells showed significant increases in both groups. The administration of the half-dose mRNA-1273 booster is safe and effective in increasing protection against SARS-CoV-2 infection.Keywords
Funding Information
- Ministry of Health of the Republic of Indonesia (PRJ-120/LPDP/2021)
This publication has 35 references indexed in Scilit:
- Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trialThe Lancet Regional Health - Western Pacific, 2023
- Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trialsVaccine, 2022
- Third dose of SARS‐CoV‐2 vaccine: A systematic review of 30 published studiesJournal of Medical Virology, 2022
- Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in JapanJournal of Infection and Chemotherapy, 2022
- Omicron variant and booster COVID-19 vaccinesThe Lancet Respiratory Medicine, 2021
- Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID‐19 infection: Prospective observational studyJournal of Medical Virology, 2021
- Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational studyThe Lancet Infectious Diseases, 2021
- Reactogenicity Following Receipt of mRNA-Based COVID-19 VaccinesJAMA, 2021
- COVID-19 vaccine decisions: considering the choices and opportunitiesMicrobes and Infection, 2021
- WHO position on the use of fractional doses – June 2017, addendum to vaccines and vaccination against yellow fever WHO: Position paper – June 2013Vaccine, 2017